Inactivated viral vaccines

Vaccine Analysis: Strategies, Principles, and Control

Volumn , Issue , 2015, Pages 45-80

  Sanders, Barbara ^a   Koldijk, Martin ^b   Schuitemaker, Hanneke ^a  

^a Janssen Infectious Diseases and Vaccines   (Netherlands)

^b CRUCELL HOLLAND BV   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84943632063     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-662-45024-6_2     Document Type: Chapter

References (214)

1. Aichinger G, Ehrlich HJ, Aaskov JG, Fritsch S, Thomasser C, Draxler W, Wolzt M, Muller M, Pinl F, Van Damme P, Hens A, Levy J, Portsmouth D, Holzer G, Kistner O, Kreil TR, Barrett PN (2011) Safety and immunogenicity of an inactivated whole virus Vero cell-derived Ross River virus vaccine: a randomized trial. Vaccine 29(50):9376-9384
2. Aldovini A, Young RA (1990) Mutations of RNA and protein sequences involved in human immunodeficiency virus type 1 packaging result in production of noninfectious virus. J Virol 64(5):1920-1926
3. Alsharifi M, Mullbacher A (2010) The gamma-irradiated influenza vaccine and the prospect of producing safe vaccines in general. Immunol Cell Biol 88(2):103-104
4. Amanna IJ, Raue HP, Slifka MK (2012) Development of a new hydrogen peroxide-based vaccine platform. Nat Med 18(6):974-979
5. Anderson MC, Baer H, Frazier DJ, Quinnan GV (1987) The role of specific IgE and betapropiolactone in reactions resulting from booster doses of human diploid cell rabies vaccine. J Allergy Clin Immunol 80(6):861-868
6. Andre FE (1995) Approaches to a vaccine against hepatitis A: development and manufacture of an inactivated vaccine. J Infect Dis 171(Suppl 1):S33-S39
7. Annunziato D, Kaplan MH, Hall WW, Ichinose H, Lin JH, Balsam D, Paladino VS (1982) Atypical measles syndrome: pathologic and serologic findings. Pediatrics 70(2):203-209
8. Armstrong ME, Giesa PA, Davide JP, Redner F, Waterbury JA, Rhoad AE, Keys RD, Provost PJ, Lewis JA (1993) Development of the formalin-inactivated hepatitis A vaccine, VAQTA from the live attenuated virus strain CR326F. J Hepatol 18(Suppl 2):S20-S26
9. Bahnemann HG (1990) Inactivation of viral antigens for vaccine preparation with particular reference to the application of binary ethylenimine. Vaccine 8(4):299-303
10. Bahri F, Letaief A, Ernez M, Elouni J, Chekir T, Ben Ammou S, Jemni L (1996) Neurological complications in adults following rabies vaccine prepared from animal brains. Presse Med 25(10):491-493
11. Bakker WA, Thomassen YE, van't Oever AG, Westdijk J, van Oijen MG, Sundermann LC, van't Veld P, Sleeman E, van Nimwegen FW, Hamidi A, Kersten GF, van den Heuvel N, Hendriks JT, van der Pol LA (2011) Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV. Vaccine 29(41):7188-7196
12. Barrett PN, Mundt W, Kistner O, Howard MK (2009) Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Rev Vaccines 8(5):607-618
13. Bazin H (2011) Pasteur and the birth of vaccines made in the laboratory. In: Plotkin SA (ed) History of vaccine development. Springer, New York, pp 39-44. doi:10.1007/978-1-4419-1339-5_6
14. Beale AJ (1961) The D-antigen content in poliovaccine as a measure of potency. Lancet 2(7213):1166-1168
15. Beardmore WB, Hook AE, Sarber RW, Mc LI Jr, Taylor AR (1957) Poliomyelitis vaccine safety testing by the tissue culture method. J Immunol 79(6):489-496
16. Beyer WE, Palache AM, Osterhaus AD (1998) Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines: a review and metaanalysis of the literature. Clin Drug Invest 15(1):1-12
17. Bodian D (1958) Control of the manufacture of poliomyelitis vaccine. In: Poliomyelitis-papers and discussions presented at the fourth international poliomyelitis conference, pp 77-85
18. Bonito RF, de Oliveira NM, Nishioka Sde A (2004) Adverse reactions associated with a Fuenzalida-Palacios rabies vaccine: a quasi-experimental study. Rev Soc Bras Med Trop 37(1):7-9
19. Bottiger M, Lycke E, Melen B, Wrange G (1958) Inactivation of poliomyelitis virus by formaldehyde; incubation time in tissue culture of formalin treated virus. Arch Gesamte Virusforsch 8(2):259-266
20. Boukhvalova MS, Prince GA, Blanco JC (2010) Inactivation of respiratory syncytial virus by zinc finger reactive compounds. Virol J 7:20
21. Bovier PA (2008) Epaxal: a virosomal vaccine to prevent hepatitis A infection. Expert Rev Vaccines 7(8):1141-1150
22. Briggs DJ (2012) The role of vaccination in rabies prevention. Curr Opin Virol 2(3):309-314
23. Brodie M, Park WH (1936) Active immunization against poliomyelitis. Am J Public Health Nations Health 26(2):119-125
24. Brown F (1993) Review of accidents caused by incomplete inactivation of viruses. Dev Biol Stand 81:103-107
25. Brown F (1995) Formaldehyde as an inactivant. Vaccine 13(2):231
26. Bruckner L, Cussler K, Halder M, Barrat J, Castle P, Duchow K, Gatewood DM, Gibert R, Groen J, Knapp B, Levis R, Milne C, Parker S, Stunkel K, Visser N, Volkers P (2003) Three Rs approaches in the quality control of inactivated rabies vaccines. The report and recommendations of ECVAM workshop 48. Altern Lab Anim 31(4):429-454
27. Budimir N, Huckriede A, Meijerhof T, Boon L, Gostick E, Price DA, Wilschut J, de Haan A (2012) Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity. PLoS ONE 7(1):e30898
28. Budowsky EI, Bresler SE, Friedman EA, Zheleznova NV (1981) Principles of selective inactivation of viral genome. I. UV-induced inactivation of influenza virus. Arch Virol 68 (3-4):239-247
29. Budowsky EI, Friedman EA, Zheleznova NV, Noskov FS (1991) Principles of selective inactivation of viral genome. VI. Inactivation of the infectivity of the influenza virus by the action of beta-propiolactone. Vaccine 9(6):398-402
30. Budowsky EI, Zalesskaya MA (1991) Principles of selective inactivation of viral genome. V. Rational selection of conditions for inactivation of the viral suspension infectivity to a given extent by the action of beta-propiolactone. Vaccine 9(5):319-325
31. Bungener L, Huckriede A, de Mare A, de Vries-Idema J, Wilschut J, Daemen T (2005) Virosomemediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity. Vaccine 23(10):1232-1241
32. Burke DS (1996) Joseph-Alexandre Auzias-Turenne, Louis Pasteur, and early concepts of virulence, attenuation, and vaccination. Perspect Biol Med 39(2):171-186
33. Campbell CH (1985) Immunogenicity of bluetongue virus inactivated by gamma irradiation. Vaccine 3(5):401-406
34. Castilow EM, Olson MR, Varga SM (2007) Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease. Immunol Res 39(1-3):225-239
35. Chandler MD, Frerichs GN (1980) Effect of metabisulphite on residual free formaldehyde estimations. J Biol Stand 8(2):145-149
36. Charney J, Fisher WP, Machlowitz RA (1957) Preparation and inactivation of purified poliovirus: comparison of vaccines derived from Mahoney and Parker poliovirus. Proc Soc Exp Biol Med 96(3):601-605
37. Chong P, Hsieh SY, Liu CC, Chou AH, Chang JY, Wu SC, Liu SJ, Chow YH, Su IJ, Klein M (2012) Production of EV71 vaccine candidates. Hum Vaccin Immunother 8(12):1775-1783
38. Clover RD, Crawford S, Glezen WP, Taber LH, Matson CC, Couch RB (1991) Comparison of heterotypic protection against influenza A/Taiwan/86 (H1N1) by attenuated and inactivated vaccines to A/Chile/83-like viruses. J Infect Dis 163(2):300-304
39. Colburn NH, Richardson RG, Boutwell RK (1965) Studies of the reaction of beta-propiolactone with deoxyguanosine and related compounds. Biochem Pharmacol 14(7):1113-1118
40. Cornfield J, Halperin M, Moore F (1956) Some statistical aspects of safety testing the Salk poliomyelitis vaccine. Public Health Rep 71(10):1045-1056
41. de Moura WC, de Araujo HP, Cabello PH, Romijn PC, Leite JP (2009) Potency evaluation of rabies vaccine for human use: the impact of the reduction in the number of animals per dilution. J Virol Methods 158(1-2):84-92
42. Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, Batalle JP, Diaz L, Trento A, Chang HY, Mitzner W, Ravetch J, Melero JA, Irusta PM, Polack FP (2009) Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 15(1):34-41
43. Di Trani L, Cordioli P, Falcone E, Lombardi G, Moreno A, Sala G, Tollis M (2003) Standardization of an inactivated H17N1 avian influenza vaccine and efficacy against A/Chicken/Italy/13474/99 high-pathogenicity virus infection. Avian Dis 47(3 Suppl):1042-1046
44. Dijkstra J (1975) In vitro reaction of beta-propiolactone and gamma-butyrolactone with glutathione and cysteine. Chem Biol Interact 10(2):115-121
45. Dong C, Liu L, Zhao H, Wang J, Liao Y, Zhang X, Na R, Liang Y, Wang L, Li Q (2011) Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys. Vaccine 29(37):6269-6275
46. Dulbecco R, Vogt M (1954) Plaque formation and isolation of pure lines with poliomyelitis viruses. J Exp Med 99(2):167-182
47. Edelman R, Ascher MS, Oster CN, Ramsburg HH, Cole FE, Eddy GA (1979) Evaluation in humans of a new, inactivated vaccine for Venezuelan equine encephalitis virus (C-84). J Infect Dis 140(5):708-715
48. Edwards KM, Dupont WD, Westrich MK, Plummer WD Jr, Palmer PS, Wright PF (1994) A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 169(1):68-76
49. Enders JF, Weller TH, Robbins FC (1949) Cultivation of the lansing strain of poliomyelitis virus in cultures of various human embryonic tissues. Science 109(2822):85-87
50. Farrell LN, Wood W, Macmorine HG, Shimada FT, Graham DG (1955) Preparation of poliomyelitis virus for production of vaccine for the 1954 field trial. Can J Public Health 46(7):265-272
51. Fermi C (1908) Uber die Immunisierung gegen Wutkranheit. Z Hyg Infectionskrankh 58:233-276
52. Fitzgerald EA, Gallagher M, Hunter WS, Seligmann EB Jr (1978) Use of the antibody assay in immunized mice for the determination of rabies vaccine potency. Dev Biol Stand 40:183-186
53. Francis T Jr, Salk JE, Brace WM (1946) The protective effect of vaccination against epidemic influenza B. J Am Med Assoc 131:275-278
54. Frenzen PD, DeBess EE, Hechemy KE, Kassenborg H, Kennedy M, McCombs K, McNees A (2001) Consumer acceptance of irradiated meat and poultry in the United States. J Food Prot 64(12):2020-2026
55. Frerichs GN, Chandler MD (1980) Estimation of residual free formaldehyde in biological products. J Biol Stand 8(2):139-144
56. Furuya Y (2012) Return of inactivated whole-virus vaccine for superior efficacy. Immunol Cell Biol 90(6):571-578
57. Furuya Y, Chan J, Regner M, Lobigs M, Koskinen A, Kok T, Manavis J, Li P, Mullbacher A, Alsharifi M (2010) Cytotoxic T cells are the predominant players providing cross-protective immunity induced by gamma -irradiated influenza A viruses. J Virol 84(9):4212-4221
58. Galea SA, Sweet A, Beninger P, Steinberg SP, Larussa PS, Gershon AA, Sharrar RG (2008) The safety profile of varicella vaccine: a 10-year review. J Infect Dis 197(Suppl 2):S165-S169
59. Gard S (1957a) Chemical inactivation of viruses. In: Wolstenholme GEW, Millar ECP (eds) Ciba foundation symposium-the nature of viruses, John Wiley & Sons Ltd., Chichester, UK. doi:10. 1002/9780470715239.ch8
60. Gard S (1957b) Inactivation of poliovirus by formaldehyde: theoretical and practical aspects. Bull World Health Organ 17(6):979-989
61. Gard S, Lycke E (1957) Inactivation of poliovirus by formaldehyde; analysis of inactivation curves. Arch Gesamte Virusforsch 7(5):471-482
62. Gard S, Lycke E, Olin G, Wesslen T (1957) Inactivation of poliomyelitis virus by formaldehyde. Arch Gesamte Virusforsch 7(2):125-135
63. Geeraedts F, Ter Veer W, Wilschut J, Huckriede A, de Haan A (2012) Effect of viral membrane fusion activity on antibody induction by influenza H5N1 whole inactivated virus vaccine. Vaccine 30(45):6501-6507
64. Gelfand T (2002) 11 January 1887, the day medicine changed: Joseph Grancher's defense of Pasteur's treatment for rabies. Bull Hist Med 76(4):698-718
65. Ghendon Y (1991) Influenza surveillance. Bull World Health Organ 69(5):509-515
66. Glenny AT, Hopkins BE (1923) Diphtheria toxoid as an immunising agent. Br J Exp Pathol 4:283-288
67. Gluck R, Mischler R, Brantschen S, Just M, Althaus B, Cryz SJ Jr (1992) Immunopotentiating reconstituted influenza virus virosome vaccine delivery system for immunization against hepatitis A. J Clin Invest 90(6):2491-2495
68. Griffin DE, Pan CH (2009) Measles: old vaccines, new vaccines. Curr Top Microbiol Immunol 330:191-212
69. Gruber WC, Taber LH, Glezen WP, Clover RD, Abell TD, Demmler RW, Couch RB (1990) Live attenuated and inactivated influenza vaccine in school-age children. Am J Dis Child 144(5):595-600
70. Gupta RK (1998) Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev 32(3):155-172
71. Haffkine WM (1899) Protective inoculation against plague and cholera. BMJ 1:35-36
72. Halstead SB, Tsai TF (2004) Japanese encephalitis vaccines. In: Bell BP, Feinstone SM (eds) Vaccines, 4th edn. Saunders Elsevier, Philadelphia
73. Hardy RW, Wertz GW (1998) The product of the respiratory syncytial virus M2 gene ORF1 enhances readthrough of intergenic junctions during viral transcription. J Virol 72(1):520-526
74. Harley D, Sleigh A, Ritchie S (2001) Ross River virus transmission, infection, and disease: a cross-disciplinary review. Clin Microbiol Rev 14(4):909-932
75. Hartman FW, Logrippo G, Kelly AR (1954) Preparation and sterilization of blood plasma. Am J Clin Pathol 24(3):339-348
76. Hartman FW, Logrippo GA (1957) Betapropiolactone in sterilization of vaccines, tissue grafts, and plasma. J Am Med Assoc 164(3):258-260
77. Hata A, Asanuma H, Rinki M, Sharp M, Wong RM, Blume K, Arvin AM (2002) Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med 347(1):26-34
78. Hayes EB (2010) Is it time for a new yellow fever vaccine?. Vaccine 28(51):8073-8076
79. Heinsbroek E, Ruitenberg EJ (2010) The global introduction of inactivated polio vaccine can circumvent the oral polio vaccine paradox. Vaccine 28(22):3778-3783
80. Heinz FX, Stiasny K (2012) Flaviviruses and flavivirus vaccines. Vaccine 30(29):4301-4306
81. Hemminki K (1981) Reactions of beta-propiolactone, beta-butyrolactone and gamma-butyrolactone with nucleic acids. Chem Biol Interact 34(3):323-331
82. Henderson DA, Witte JJ, Morris L, Langmuir AD (1964) Paralytic disease associated with oral polio vaccines. JAMA 190:41-48
83. Herzog C, Hartmann K, Kunzi V, Kursteiner O, Mischler R, Lazar H, Gluck R (2009) Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine. Vaccine 27(33):4381-4387
84. Hess RD, Weber F, Watson K, Schmitt S (2012) Regulatory, biosafety and safety challenges for novel cells as substrates for human vaccines. Vaccine 30(17):2715-2727
85. Hueper WC (1963) Environmental carcinogenesis in man and animals. Ann NY Acad Sci 108:963-1038
86. Jiang B, Gentsch JR, Glass RI (2008a) Inactivated rotavirus vaccines: a priority for accelerated vaccine development. Vaccine 26(52):6754-6758
87. Jiang B, Wang Y, Saluzzo JF, Bargeron K, Frachette MJ, Glass RI (2008b) Immunogenicity of a thermally inactivated rotavirus vaccine in mice. Hum Vaccin 4(2):143-147
88. John TJ (2002) Vaccine-associated paralytic polio in India. Bull World Health Organ 80(11):917
89. Johnson TR, Graham BS (2004) Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection. Pediatr Infect Dis J 23(1 Suppl):S46-S57
90. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE (1969) An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 89(4):405-421
91. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH (1969) Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89(4):422-434
92. Kumar M, Sudeep AB, Arankalle VA (2012) Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus. Vaccine 30(43):6142-6149
93. Larghi OP, Nebel AE (1980) Rabies virus inactivation by binary ethylenimine: new method for inactivated vaccine production. J Clin Microbiol 11(2):120-122
94. Lawrence SA (1999) Beta-propiolactone and aziridine: their applications in organic synthesis and viral inactivation. Chim Oggi 17:51-54
95. Lawrence SA (2000) beta-Propiolactone: viral inactivation in vaccines and plasma products. PDA J Pharm Sci Technol 54(3):209-217
96. Levine MJ, Ellison MC, Zerbe GO, Barber D, Chan C, Stinson D, Jones M, Hayward AR (2000) Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicellaspecific immune response in seropositive people 55 years of age and older. Vaccine 18(25):2915-2920
97. Li YP, Liang ZL, Gao Q, Huang LR, Mao QY, Wen SQ, Liu Y, Yin WD, Li RC, Wang JZ (2012) Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial. Vaccine 30(22):3295-3303
98. Lindsey NP, Schroeder BA, Miller ER, Braun MM, Hinckley AF, Marano N, Slade BA, Barnett ED, Brunette GW, Horan K, Staples JE, Kozarsky PE, Hayes EB (2008) Adverse event reports following yellow fever vaccination. Vaccine 26(48):6077-6082
99. Linley E, Denyer SP, McDonnell G, Simons C, Maillard JY (2012) Use of hydrogen peroxide as a biocide: new consideration of its mechanisms of biocidal action. J Antimicrob Chemother 67(7):1589-1596
100. Ljungman P (2012) Vaccination of immunocompromised patients. Clin Microbiol Infect 18(Suppl 5):93-99
101. Logrippo GA (1960) Investigations of the use of beta-propiolactone in virus inactivation. Ann NY Acad Sci 83:578-594
102. Lycke E, Melen B, Wrange G (1957) Studies of the inactivation of poliomyelitis virus by formaldehyde. Arch Gesamte Virusforsch 7(4):378-383
103. Madhusudana SN, Shamsundar R, Seetharaman S (2004) In vitro inactivation of the rabies virus by ascorbic acid. Int J Infect Dis 8(1):21-25
104. Mahmood K, Pelkowski S, Atherly D, Sitrin R, Donnelly JJ (2013) Hexavalent IPV-based combination vaccines for public-sector markets of low-resource countries: a product review. Hum Vaccin Immunother 9(9):1894-1902
105. Marennikova SS, Macevic GR (1975) Experimental study of the role of inactivated vaccine in twostep vaccination against smallpox. Bull World Health Organ 52(1):51-56
106. Martin SS, Bakken RR, Lind CM, Garcia P, Jenkins E, Glass PJ, Parker MD, Hart MK, Fine DL (2010a) Comparison of the immunological responses and efficacy of gamma-irradiated V3526 vaccine formulations against subcutaneous and aerosol challenge with Venezuelan equine encephalitis virus subtype IAB. Vaccine 28(4):1031-1040
107. Martin SS, Bakken RR, Lind CM, Garcia P, Jenkins E, Glass PJ, Parker MD, Hart MK, Fine DL (2010b) Evaluation of formalin inactivated V3526 virus with adjuvant as a next generation vaccine candidate for Venezuelan equine encephalitis virus. Vaccine 28(18):3143-3151
108. Mate U, Solomon JJ, Segal A (1977) In vitro binding of beta-propiolactone to calf thymus DNA and mouse liver DNA to form 1-(2-carboxyethyl) adenine. Chem Biol Interact 18(3):327-336
109. Maves RC, Ore RM, Porter KR, Kochel TJ (2011) Immunogenicity and protective efficacy of a psoralen-inactivated dengue-1 virus vaccine candidate in Aotus nancymaae monkeys. Vaccine 29(15):2691-2696
110. McMinn PC (2002) An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev 26(1):91-107
111. Meier P (1957) Safety testing of poliomyelitis vaccine. Science 125(3257):1067-1071
112. Melnick JL (1991) Virus inactivation: lessons from the past. Dev Biol Stand 75:29-36
113. Metz B, Kersten GF, Baart GJ, de Jong A, Meiring H, ten Hove J, van Steenbergen MJ, Hennink WE, Crommelin DJ, Jiskoot W (2006) Identification of formaldehyde-induced modifications in proteins: reactions with insulin. Bioconjug Chem 17(3):815-822
114. Metz B, Kersten GF, Hoogerhout P, Brugghe HF, Timmermans HA, de Jong A, Meiring H, ten Hove J, Hennink WE, Crommelin DJ, Jiskoot W (2004) Identification of formaldehydeinduced modifications in proteins: reactions with model peptides. J Biol Chem 279(8):6235-6243
115. Midthun K, Ellerbeck E, Gershman K, Calandra G, Krah D, McCaughtry M, Nalin D, Provost P (1991) Safety and immunogenicity of a live attenuated hepatitis A virus vaccine in seronegative volunteers. J Infect Dis 163(4):735-739
116. Moghaddam A, Olszewska W, Wang B, Tregoning JS, Helson R, Sattentau QJ, Openshaw PJ (2006) A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat Med 12(8):905-907
117. Monath TP, Fowler E, Johnson CT, Balser J, Morin MJ, Sisti M, Trent DW (2011) An inactivated cell-culture vaccine against yellow fever. N Engl J Med 364(14):1326-1333
118. Morgeaux S, Milne C, Daas A (2005) Feasibility study to develop a common in vitro D antigen assay for inactivated poliomyelitis vaccines. Pharmeuropa Bio 2005(1):19-26
119. Murphy BR, Walsh EE (1988) Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol 26(8):1595-1597
120. Nathanson N, Langmuir AD (1963) The cutter incident. poliomyelitis following formaldehydeinactivated poliovirus vaccination in the United States during the Spring of 1955. II. Relationship of poliomyelitis to cutter vaccine. Am J Hyg 78:29-60
121. Neuzil KM, Dupont WD, Wright PF, Edwards KM (2001) Efficacy of inactivated and coldadapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. Pediatr Infect Dis J 20(8):733-740
122. Nicholson KG, Tyrrell DA, Harrison P, Potter CW, Jennings R, Clark A, Schild GC, Wood JM, Yetts R, Seagroatt V, Huggins A, Anderson SG (1979) Clinical studies of monovalent inactivated whole virus and subunit A/USSR/77 (H1N1) vaccine: serological responses and clinical reactions. J Biol Stand 7(2):123-136
123. Nicholson KG, Wood JM, Zambon M (2003) Influenza. Lancet 362(9397):1733-1745
124. Nims RW, Plavsic M (2012) Polyomavirus inactivation-A review. Biologicals 41(2):63-70
125. Offit PA (2005) The cutter incident, 50 years later. N Engl J Med 352(14):1411-1412
126. Offit PA, Dudzik KI (1989) Noninfectious rotavirus (strain RRV) induces an immune response in mice which protects against rotavirus challenge. J Clin Microbiol 27(5):885-888
127. Ozaki Y, Melnick JL (1963) Reaction of poliovirus and formaldehyde in magnesium chloride solution to enhance potency of killed-virus vaccine. J Immunol 90:429-437
128. Paiva TM, Benega MA, Silva DB, Santos KC, Cruz AS, Hortenci MF, Barbieri MT, Monteiro MM, Barbosa HA, Carvalhanas TR (2013) Evolutionary pattern of reemerging influenza B/Victoria lineage viruses in Sao Paulo, Brazil, 1996-2012: implications for vaccine composition strategy. J Med Virol 85(11):1983-1989
129. Pasteur L, Chamberland CE, Roux E (1885) Methode pour prevenir la rage après morsue. C R Acad Sci (101):765-774 (in French)
130. Patel MM, Haber P, Baggs J, Zuber P, Bines JE, Parashar UD (2009) Intussusception and rotavirus vaccination: a review of the available evidence. Expert Rev Vaccines 8(11):1555-1564
131. Peck FB Jr, Powell HM, Culbertson CG (1955) A new antirabies vaccine for human use; clinical and laboratory results using rabies vaccine made from embryonated duck eggs. J Lab Clin Med 45(5):679-683
132. Perrin P, Morgeaux S (1995) Inactivation of DNA by beta-propiolactone. Biologicals 23(3):207-211
133. Ph. Eur. (2011a) Free formaldehyde. In: Pharmacopoeia E (ed) European Pharmacopoeia, 7th edn, vol 01/2008:20418
134. Ph. Eur. (2011b) Hepatitis A vaccine (inactivataed, adsorbed). In: Pharmacopoeia E (ed) European Pharmacopoeia 7.0
135. Ph. Eur. (2011c) Influenza vaccine (whole virion, inactivated). In: Pharmacopoeia E (ed) European Pharmacopoeia, 7th ed, pp 795-798
136. Ph. Eur. (2011d) Poliomyelitis vaccine (inactivated). In: Pharmacopoeia E (ed) European Pharmacopoeia, 7th edn
137. Ph. Eur. (2011e) Rabies vaccine for human use prepared in cell cultures. In: Pharmacopoeia E (ed) European Pharmacopoeia 7th edn, pp 822-824
138. Ph. Eur. (2011f) Tick borne encephalitis vaccine (inactivated). In: Pharmacopoeia E (ed) European Pharmacopoeia, 7th edn, pp 834-836
139. Pittman P, Plotkin SA (2004) Miscellaneous limited-use vaccines. In: Bell BP, Feinstone SM (eds) Vaccines, 4th edn. Saunders Elsevier, Philadelphia
140. Plotkin SA, Vidor E (2004) Hepatitis A vaccine. In: Bell BP, Feinstone SM (eds) Vaccines, 4th edn. Saunders Elsevier, Philadelphia
141. Poirier B, Variot P, Delourme P, Maurin J, Morgeaux S (2010) Would an in vitro ELISA test be a suitable alternative potency method to the in vivo immunogenicity assay commonly used in the context of international hepatitis A vaccines batch release?. Vaccine 28(7):1796-1802
142. Polack FP, Auwaerter PG, Lee SH, Nousari HC, Valsamakis A, Leiferman KM, Diwan A, Adams RJ, Griffin DE (1999) Production of atypical measles in rhesus macaques: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion-inhibiting antibody. Nat Med 5(6):629-634
143. Polack FP, Hoffman SJ, Crujeiras G, Griffin DE (2003) A role for nonprotective complementfixing antibodies with low avidity for measles virus in atypical measles. Nat Med 9(9):1209-1213
144. Provost PJ, Bishop RP, Gerety RJ, Hilleman MR, McAleer WJ, Scolnick EM, Stevens CE (1986a) New findings in live, attenuated hepatitis A vaccine development. J Med Virol 20(2):165-175
145. Provost PJ, Hilleman MR (1979) Propagation of human hepatitis A virus in cell culture in vitro. Proc Soc Exp Biol Med 160(2):213-221
146. Provost PJ, Hughes JV, Miller WJ, Giesa PA, Banker FS, Emini EA (1986b) An inactivated hepatitis A viral vaccine of cell culture origin. J Med Virol 19(1):23-31
147. Putnak RJ, Coller BA, Voss G, Vaughn DW, Clements D, Peters I, Bignami G, Houng HS, Chen RC, Barvir DA, Seriwatana J, Cayphas S, Garcon N, Gheysen D, Kanesa-Thasan N, McDonell M, Humphreys T, Eckels KH, Prieels JP, Innis BL (2005) An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 23(35):4442-4452
148. Rappuoli R (1994) Toxin inactivation and antigen stabilization: two different uses of formaldehyde. Vaccine 12(7):579-581
149. Redman RL, Nader S, Zerboni L, Liu C, Wong RM, Brown BW, Arvin AM (1997) Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J Infect Dis 176(3):578-585
150. Reitman M, Tonik EJ (1971) Immunity to aerosol challenge in guinea pigs immunized with gamma-irradiated Venezuelan equine encephalitis vaccines. Appl Microbiol 21(4):688-692
151. Reitman M, Tribble HR Jr, Green L (1970) Gamma-irradiated Venezuelan equine encephalitis vaccines. Appl Microbiol 19(5):763-767
152. Rendi-Wagner P (2008) Advances in vaccination against tick-borne encephalitis. Expert Rev Vaccines 7(5):589-596
153. Rice WG, Supko JG, Malspeis L, Buckheit RW Jr, Clanton D, Bu M, Graham L, Schaeffer CA, Turpin JA, Domagala J, Gogliotti R, Bader JP, Halliday SM, Coren L, Sowder RC 2nd, Arthur LO, Henderson LE (1995) Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDS. Science 270(5239):1194-1197
154. Roberts A, Lamirande EW, Vogel L, Baras B, Goossens G, Knott I, Chen J, Ward JM, Vassilev V, Subbarao K (2010) Immunogenicity and protective efficacy in mice and hamsters of a betapropiolactone inactivated whole virus SARS-CoV vaccine. Viral Immunol 23(5):509-519
155. Roberts JJ, Warwick GP (1963) The reaction of beta-propiolactone with guanosine, deoxyguanylic acid and RNA. Biochem Pharmacol 12:1441-1442
156. Rooijakkers E, Groen J, Uittenbogarrd J, van Herwijnen J, Osterhaus A (1996a) Development and evaluation of alternative testing methods for the in vivo NIH potency test used for the quality control of inactivated rabies vaccines. Dev Biol Stand 86:137-145
157. Rooijakkers EJ, Uittenbogaard JP, Groen J, Osterhaus AD (1996b) Rabies vaccine potency control: comparison of ELISA systems for antigenicity testing. J Virol Methods 58 (1-2):111-119
158. Rossio JL, Esser MT, Suryanarayana K, Schneider DK, Bess JW Jr, Vasquez GM, Wiltrout TA, Chertova E, Grimes MK, Sattentau Q, Arthur LO, Henderson LE, Lifson JD (1998) Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J Virol 72(10):7992-8001
159. Salk JE (1953) Studies in human subjects on active immunization against poliomyelitis. I. A preliminary report of experiments in progress. J Am Med Assoc 151(13):1081-1098
160. Salk JE (1955) Vaccination against paralytic poliomyelitis performance and prospects. Am J Public Health Nations Health 45(5 Pt 1):575-596
161. Salk JE, Francis T Jr (1946) Immunization against influenza. Ann Intern Med 25:443-452
162. Salk JE, Gori JB (1960) A review of theoretical, experimental, and practical considerations in the use of formaldehyde for the inactivation of poliovirus. Ann NY Acad Sci 83:609-637
163. Salk JE, Krech U, Youngner JS, Bennett BL, Lewis LJ, Bazeley PL (1954) Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines. Am J Public Health Nations Health 44(5):563-570
164. Salmon DE, Smith T (1886) On a new method of producing immunity from contagious diseases. Am Vet Rev 10:63-69 (First published)
165. Schultz-Cherry S, Jones JC (2010) Influenza vaccines: the good, the bad, and the eggs. Adv Virus Res 77:63-84
166. Schultz P, Rightsel WA, Timm EA, Taylor AR, Mc LI Jr (1957) Partially inactivated poliomyelitis virus: initiation of infection in tissue culture. J Immunol 79(6):497-507
167. Segal A, Solomon JJ, Mignano J, Dino J (1981) The isolation and characterization of 3-(2-carboxyethyl)cytosine following in vitro reaction of beta-propiolactone with calf thymus DNA. Chem Biol Interact 35(3):349-361
168. Semple D (1911) The preparation of a safe and efficient antirabic vaccine. Scientific Memoirs by Officers of the Medical and Sanitary Departments of India, vol 44. Superintendent Government Printing, Calcutta. https://archive.org/stream/preparationofsaf00sempuoft#page/n5/mode/2up
169. Shafique M, Wilschut J, de Haan A (2012) Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands. Vaccine 30(3):597-606
170. Skykes G (1965) The theory and mode of action of disinfection. In: Lippincott (ed) Disinfection and sterilization, Philadelphia
171. Smorodintsev AA, Ilyenko VI (1969) Results of laboratory and epidemiological study of vaccination against tick-borne encephalitis. In: Libíková H (ed) Biology of viruses of the tickborne encephalitis complex, Smolenice, 11-14 October 1960, pp 332-343
172. Stauffer F, El-Bacha T, Da Poian AT (2006) Advances in the development of inactivated virus vaccines. Recent Pat Antiinfect Drug Discov 1(3):291-296
173. Steele KE, Reed DS, Glass PJ, Hart MK, Ludwig GV, Pratt WD (2007) Aplhavirus Encephalitides. In: Dembek ZF (ed) Medical aspects of biological warfare. Office of the Surgeon General, US Army Medical Department Center and School, Borden Institute, Washington DC, pp 241-270
174. Stokes J, Chenoweth AD, Waltz AD, Gladen RG, Shaw D (1937) Results of immunization by means of active virus of human influenza. J Clin Invest 16(2):237-243
175. Sugawara K, Nishiyama K, Ishikawa Y, Abe M, Sonoda K, Komatsu K, Horikawa Y, Takeda K, Honda T, Kuzuhara S, Kino Y, Mizokami H, Mizuno K, Oka T, Honda K (2002) Development of Vero cell-derived inactivated Japanese encephalitis vaccine. Biologicals 30(4):303-314
176. Swanson MC, Rosanoff E, Gurwith M, Deitch M, Schnurrenberger P, Reed CE (1987) IgE and IgG antibodies to beta-propiolactone and human serum albumin associated with urticarial reactions to rabies vaccine. J Infect Dis 155(5):909-913
177. Termini J (2000) Hydroperoxide-induced DNA damage and mutations. Mutat Res 450 (1-2):107-124
178. Thaysen-Andersen M, Jorgensen SB, Wilhelmsen ES, Petersen JW, Hojrup P (2007) Investigation of the detoxification mechanism of formaldehyde-treated tetanus toxin. Vaccine 25(12):2213-2227
179. Uittenbogaard JP, Zomer B, Hoogerhout P, Metz B (2011) Reactions of beta-propiolactone with nucleobase analogues, nucleosides, and peptides: implications for the inactivation of viruses. J Biol Chem 286(42):36198-36214
180. USFDA (1998) Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin, Appendix 3. ICH guidance for industry Q5A. United States Food and Drug Administration
181. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J (2007) Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39(1):44-84
182. van Steenis G, van Wezel AL, Sekhuis VM (1981) Potency testing of killed polio vaccine in rats. Dev Biol Stand 47:119-128
183. Verdijk P, Rots NY, Bakker WA (2011) Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains. Expert Rev Vaccines 10(5):635-644
184. Verma R, Khanna P, Chawla S (2012) Influenza vaccine: an effective preventive vaccine for developing countries. Hum Vaccin Immunother 8(5):675-678
185. Vidor E, Fritzell B, Plotkin S (1996) Clinical development of a new inactivated hepatitis A vaccine. Infection 24(6):447-458
186. Wang Y, Azevedo M, Saif LJ, Gentsch JR, Glass RI, Jiang B (2010) Inactivated rotavirus vaccine induces protective immunity in gnotobiotic piglets. Vaccine 28(33):5432-5436
187. Wassilak SGF, Roper MH, Murphy TV, Orenstein WA (2004) Tetanus toxoid. In: Bell BP, Feinstone SM (eds) Vaccines, 4th edn. Saunders Elsevier, Philadelphia
188. Weller TH, Robbins FC, Enders JF (1949) Cultivation of poliomyelitis virus in cultures of human foreskin and embryonic tissues. Proc Soc Exp Biol Med 72(1):153-155
189. Westdijk J, Brugmans D, Martin J, van't Oever A, Bakker WA, Levels L, Kersten G (2011) Characterization and standardization of Sabin based inactivated polio vaccine: proposal for a new antigen unit for inactivated polio vaccines. Vaccine 29(18):3390-3397
190. White (1955) Technical report on Salk poliomyelitis vaccine. U.S. Public Health Service, Washington DC
191. WHO (1984) WHO expert committee on rabies. World Health Organization technical report series, vol 709
192. WHO (1995) Requirements for hepatitis A vaccine (inactivated). Requirements for biological substances № 49.
193. World Health Organization WHO (1999) Requirements for tick-borne encephalitis vaccine (inactivated). Requirements for biological substances № 51, WHO technical report series, № 889, 1999.
194. World Health Organization, Geneva WHO (2000) Recommended composition of influenza virus vaccines for use in the 2001 influenza season. Wkly Epidemiol Rec 75:61-65.
195. World Health Organization WHO (2002) Recommendations for the production and control of poliomyelitis vaccine (inactivated). WHO technical report series 910, Annex 2. Geneva
196. WHO (2005) WHO expert consultation on rabies. World Health Organization technical report series, vol 931. World Health Organization, Geneva
197. WHO (2006a) Inactivated poliovirus vaccine following oral poliovirus vaccine cessation. Wkly Epidemiol Rec 81(15):137-144
198. WHO (2006b) Japanese encephalitis vaccines. Wkly Epidemiol Rec 81:331-340 (World Health Organization, Geneva)
199. WHO (2007a) Recommendations for inactivated rabies vaccine for human use produced in cell substrates and embryonated eggs. WHO technical report series, No 941. World Health Organization, Geneva
200. WHO (2007b) Recommendations for Japanese encephalitis vaccine (inactivated) for human use.
201. WHO Expert Committee on Biological Standardization. World Health Organization, Geneva WHO (2009a) Recommended composition of influenza virus vaccines for use in the 2009-2010 influenza season (northern hemisphere winter). Wkly Epidemiol Rec 84:421-431 (World Health Organization, Geneva)
202. WHO (2009b) Update on improving IPV. The Polio pipeline. World Health Organization, Geneva
203. WHO (2009c) WHO global action plan to minimize poliovirus facility associated risk after eradication of wild polioviruses and cessation of routine OPV use. World Health Organization, Geneva
204. WHO (2011) Vaccines against tick-borne encephalitis: WHO position paper. Wkly Epidemiol Rec 86:241-256 (World Health Organization, Geneva)
205. Wiktor TJ, Aaslestad HG, Kaplan MM (1972) Immunogenicity of rabies virus inactivated by -propiolactone, acetylethyleneimine, and ionizing irradiation. Appl Microbiol 23(5):914-918
206. Wilde JA, McMillan JA, Serwint J, Butta J, O'Riordan MA, Steinhoff MC (1999) Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA 281(10):908-913
207. Wood JM, Williams MS (1998) History of inactivated influenza vaccines. In: Nicholson KGW, Webster RG, Hay AJ (ed) Textbook of influenza. Blackwell Science, Oxford, pp 324-345
208. Wright AE, Semple D (1897) Remarks on vaccination against typhoid fever. Br Med J 1(1883):256-259
209. Wu X, Smith TG, Rupprecht CE (2011) From brain passage to cell adaptation: the road of human rabies vaccine development. Expert Rev Vaccines 10(11):1597-1608
210. Zacks MA, Paessler S (2009) Encephalitic alphaviruses. Vet Microbiol 140(3-4):281-286
211. Zehrung D (2010) Improving the affordability of Inactivated Poliovirus Vaccines (IPV) for use in low- and middle-income countries. An economic analysis of strategies to reduce the cose of routine IPV immunization. PATH, Seattle
212. Zepp F (2011) Principles of vaccine design-lessons from nature. Vaccine 28(Suppl 3):C14-C24
213. Zhu FC, Liang ZL, Li XL, Ge HM, Meng FY, Mao QY, Zhang YT, Hu YM, Zhang ZY, Li JX, Gao F, Chen QH, Zhu QY, Chu K, Wu X, Yao X, Guo HJ, Chen XQ, Liu P, Dong YY, Li FX, Shen XL, Wang JZ (2013) Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet 381:1037-1045
214. Zissis G, Lambert JP, Marbehant P, Marissens D, Lobmann M, Charlier P, Delem A, Zygraich N (1983) Protection studies in colostrum-deprived piglets of a bovine rotavirus vaccine candidate using human rotavirus strains for challenge. J Infect Dis 148(6):1061-1068